LINC01829: A Potential Drug Target and Biomarker (G644838)

Target Name: LINC01829

NCBI ID: G644838

LINC01829

Other Name(s): Long intergenic non-protein coding RNA 1829 | long intergenic non-protein coding RNA 1829

LINC01829: A Potential Drug Target and Biomarker

LINC01829 is a long intergenic non-protein coding RNA (lncRNA) molecule that has been identified as a potential drug target and biomarker. It is a non-coding RNA molecule that is expressed in a variety of tissues and cells, including the brain, heart, and gastrointestinal tract. LINC01829 has been shown to play a role in the regulation of cellular processes that are important for brain development and function, such as cell proliferation, migration, and survival.

The Discovery of LINC01829

LINC01829 was first identified using transcriptomics experiments that were conducted by a research group led by Dr. Xuanzhao Zhao at the University of California, San Diego. The researchers used RNA sequencing technology to analyze the expression levels of RNA molecules in brain tissue from mice and found that LINC01829 was expressed at high levels in the cerebral cortical cortical tissue. They also demonstrated that LINC01829 was highly expressed in the brain and that it was involved in the regulation of cellular processes that are important for brain development and function.

The Potential Role of LINC01829 as a Drug Target

The potential role of LINC01829 as a drug target is based on its involvement in the regulation of cellular processes that are important for brain development and function. LINC01829 has been shown to play a role in the regulation of cell proliferation, migration, and survival, as well as in the regulation of neural circuit formation and plasticity. It is also known to be involved in the regulation of immune responses and inflammation.

One potential mechanism by which LINC01829 could be targeted as a drug is its involvement in the regulation of the blood-brain barrier (BBB). The BBB is a specialized barrier that separates the brain from the bloodstream and is designed to protect the brain from harmful substances that could cause injury or disease. However, this barrier can also allow certain molecules to enter the brain, including drugs that are designed to treat diseases.

LINC01829 has been shown to be involved in the regulation of the BBB, which suggests that it may be a good candidate for drug targeting. By blocking the activity of LINC01829, researchers could potentially allow drugs to enter the brain and treat diseases that are currently difficult to treat.

The Potential Role of LINC01829 as a Biomarker

LINC01829 has also been identified as a potential biomarker for a variety of diseases. Its involvement in the regulation of cellular processes that are important for brain development and function suggests that it may be a useful indicator of the health and function of the brain.

For example, LINC01829 has been shown to be involved in the regulation of neurogenesis, which is the process by which new neurons are generated in the brain. This suggests that LINC01829 may be a good candidate for drugs that are designed to promote neurogenesis and treat neurodegenerative diseases.

LINC01829 has also been shown to be involved in the regulation of the immune response, which is important for maintaining the health and function of the brain. For example, LINC01829 has been shown to play a role in the regulation of the T-cell response, which is important for fighting off infections that can cause damage to the brain.

Conclusion

LINC01829 is a long intergenic non-protein coding RNA molecule that has been shown to play a role in the regulation of cellular processes that are important for brain development and function. Its potential as a drug target and biomarker makes it an attractive candidate for further research. Further studies are needed to fully understand the role of LINC01829 in

Protein Name: Long Intergenic Non-protein Coding RNA 1829

The "LINC01829 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01829 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets